SEC Form 4 · accession 0001179110-16-020456
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ravindra Kumar
Officer — VP & Chief Scientific Officer
Period of report
Feb 25, 2016
Accepted (ET)
Feb 29, 2016 · 5:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 25, 2016 | M | 8,000 | $3.88 | A | 78,751 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $3.88 | Feb 25, 2016 | M | 8,000 | D | — | Dec 2, 2020 | Common Stock | 8,000 | 5,515 | D |
Explanation of responses
- F1The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.